

# Datasheet: HCA211 BATCH NUMBER 152019

Description:	HUMAN ANTI USTEKINUMAB
Specificity:	USTEKINUMAB
Other names:	Stelara <sup>®</sup>
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD17829_hlgG1
Isotype:	lgG1
Quantity:	0.1 mg

## **Product Details**

	Ap	pΙ	ic	ati	o	ทร
--	----	----	----	-----	---	----

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <a href="www.bio-rad-antibodies.com/protocols">www.bio-rad-antibodies.com/protocols</a>.

No

ELISA	•			
Where this product has not been tested for use in a particular technique this does not				
necessarily exclude its us	se in such procedures. Suggested working dilutions are given as			
a guide only. It is recommended that the user titrates the product for use in their own				
system using appropriate	e negative/positive controls.			

**Not Determined** 

**Suggested Dilution** 

Product Form

Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation

Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

Yes

Buffer Solution Phosphate buffered saline

Preservative Stabilisers 0.01% Thiomersal

Approx. Protein Concentrations Antibody concentration 0.5 mg/ml

Ustekinumab

#### **Specificity**

**Human Anti-Ustekinumab Antibody, clone AbD17829\_hlgG1** is a paratope specific, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug ustekinumab and inhibits binding to its target.

Clone AbD17827\_hlgG1 is a fully human recombinant monoclonal antibody with lgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay.

Ustekinumab (Stelara) is a fully human monoclonal antibody drug (IgG1/kappa) that has been approved in US, Canada, and Europe for the treatment of plaque psoriasis and psoriatic arthritis. The FDA approved the medication for the treatment of moderate-severe Crohn's disease in 2016. The drug blocks interleukin IL-12 and IL-23 by binding with high affinity and specificity to the p40 subunit, preventing the binding of these two cytokines to T-lymphocytes, and thereby disrupting the proinflammatory pathway.

#### View a summary of all anti-ustekinumab antibodies

#### **Affinity**

The monovalent intrinsic affinity of AbD17829 was measured as  $K_D$  = 2.8 nM by real time, label free molecular interaction analysis on immobilized ustekinumab.

#### **ELISA**

This product may be used in an indirect ELISA or as a detection antibody when conjugated to HRP in a bridging ELISA together with AbD18334 (<u>HCA209</u>) as the capture reagent. Conjugation of this antibody to HRP can be undertaken using a Lynx Rapid HRP conjugation kit, these kits may be purchased from Bio-Rad.

Protocol: <u>PK bridging ELISA to measure free drug</u> Protocol: <u>ADA bridging ELISA</u>

# Storage

Store at +4°C or at -20°C if preferred.

Storage in frost-free freezers is not recommended.

This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

#### Guarantee

12 months from date of despatch

#### Acknowledgements

Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.

# Health And Safety Information

Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA211

10094

#### **Licensed Use**

For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

## Regulatory

For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody

technology can be found in the HuCAL Antibodies Technical Manual

## Related Products

# **Recommended Useful Reagents**

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK001P)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK003P)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK004P)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK005P)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK006P)

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M371631:200612'

#### Printed on 01 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint